Your session is about to expire
← Back to Search
Adherence Intervention for Medication Adherence
N/A
Waitlist Available
Led By Bethany J Foster, MD, MSCE
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
Study Summary
This trial is testing a new way to help young people take their medication after a kidney transplant, which is important because poor medication adherence contributes to graft failure.
Eligible Conditions
- Medication Adherence
- Kidney Transplant
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Taking Adherence
Timing Adherence
Secondary outcome measures
Self-reported Taking Adherence
Self-reported Timing Adherence
Other outcome measures
Acceptability of e-pillbox: PSSUQ
Acceptability of tracking website: PSSUQ
Drop out rate
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Healthy Living Education InterventionExperimental Treatment1 Intervention
Patient-participants will receive a healthy living education intervention with the use of an e-pillbox. Contacts with the coach will occur at the same intervals as at adherence intervention sites. Participants will choose one of 3 healthy living topics on which they will receive education in an interactive format. The coach will engage the participant in a semi-scripted conversation on the selected topic. At check-ins, the coach will either continue the conversation on the topic selected at the outset or provide education on another topic. The coach will NOT engage in discussions about adherence and will NOT provide feedback on adherence data.
Group II: Adherence InterventionExperimental Treatment1 Intervention
The objective of the intervention is to improve medication adherence. Patient-participants will use a multi-dose electronic pillbox and adherence tracking website which can provide dose reminders. Patient will form an Adherence Support Team (AST) including the participant, a parent (or other) and the "Coach" (study coordinator). The Coach will guide the AST to use Action-focused Problem-solving to address personal barriers to adherence. They will then generate concrete "if-then" plans for how they will behave in a given situation. Intervention participants with excellent adherence will be encouraged to work on building autonomy in medication-taking instead of adherence. Action plans will be able to be modified, if desired, at the 6-week and 10-week check-ins.
HCP-participants at intervention sites will be given the option to login to the adherence tracking website to view the adherence data of their patients. They will also be alerted by study staff to critical non-adherence events.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Adherence Intervention
2022
N/A
~5860
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
442 Previous Clinical Trials
159,078 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,356 Previous Clinical Trials
4,314,970 Total Patients Enrolled
Bethany J Foster, MD, MSCEPrincipal InvestigatorMontreal Children's Hospital of the MUHC
3 Previous Clinical Trials
303 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger